Clinical Trials

A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination with Atezolizumab Compared with Atezolizumab as Maintenance Therapy in Participants with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Sherri Cervantez, MD

For more information about this study
View Details

About This Study